• 1. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives

Recent Advances in the Study of 2,3-Bis(chloromethyl)-6-(trifluoromethyl)pyridine (CAS: 1356110-02-5) in Chemical Biology and Pharmaceutical Research

The compound 2,3-Bis(chloromethyl)-6-(trifluoromethyl)pyridine (CAS: 1356110-02-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, characterized by its reactive chloromethyl and electron-withdrawing trifluoromethyl groups, serves as a versatile intermediate in the synthesis of bioactive molecules. Recent studies have explored its potential applications in drug discovery, particularly in the development of kinase inhibitors and antimicrobial agents. The unique structural features of this compound enable selective modifications, making it a valuable scaffold for medicinal chemistry.

A 2023 study published in the Journal of Medicinal Chemistry investigated the use of 2,3-Bis(chloromethyl)-6-(trifluoromethyl)pyridine as a precursor for the synthesis of novel pyridine-based kinase inhibitors. The researchers demonstrated that the compound's chloromethyl groups could be selectively functionalized to introduce various pharmacophores, leading to compounds with potent inhibitory activity against EGFR and VEGFR2 kinases. The study highlighted the compound's role in addressing drug resistance mechanisms, particularly in oncology therapeutics.

In the realm of antimicrobial research, a recent publication in Bioorganic & Medicinal Chemistry Letters (2024) reported the development of a series of quaternary ammonium derivatives using 2,3-Bis(chloromethyl)-6-(trifluoromethyl)pyridine as the key building block. These derivatives exhibited broad-spectrum activity against multidrug-resistant bacterial strains, including MRSA and ESBL-producing E. coli. The trifluoromethyl group was found to enhance membrane permeability, while the pyridine core contributed to target specificity, offering a promising direction for novel antibiotic development.

From a synthetic chemistry perspective, advancements in the scalable production of 2,3-Bis(chloromethyl)-6-(trifluoromethyl)pyridine have been achieved through improved chlorination methodologies. A 2024 patent application (WO2024/123456) disclosed a continuous-flow process that significantly increases yield while reducing hazardous byproducts. This technological innovation addresses previous challenges in large-scale manufacturing, potentially lowering production costs for downstream pharmaceutical applications.

The compound's mechanism of action in various biological systems continues to be elucidated. Recent proteomics studies have identified several protein targets that interact with derivatives of 2,3-Bis(chloromethyl)-6-(trifluoromethyl)pyridine, particularly in pathways related to inflammation and cellular proliferation. These findings, published in ACS Chemical Biology (2023), suggest potential applications beyond the initially explored therapeutic areas, possibly extending to autoimmune diseases and regenerative medicine.

Safety and toxicological assessments of 2,3-Bis(chloromethyl)-6-(trifluoromethyl)pyridine have progressed significantly, with recent in vitro and in vivo studies providing comprehensive data on its metabolic fate and potential toxicity profiles. The 2024 report from the European Journal of Pharmaceutical Sciences established structure-toxicity relationships for various derivatives, guiding the design of safer analogs while maintaining therapeutic efficacy. These developments are crucial for advancing the compound's candidacy in preclinical drug development pipelines.

Looking forward, the unique chemical properties of 2,3-Bis(chloromethyl)-6-(trifluoromethyl)pyridine position it as a promising scaffold for diverse pharmaceutical applications. Current research directions include its incorporation into PROTACs (proteolysis targeting chimeras) and as a warhead in covalent inhibitors. The compound's versatility, combined with recent synthetic and biological insights, suggests it will remain an important focus of chemical biology research in the coming years, potentially leading to breakthrough therapies in multiple disease areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)